pre-IPO PHARMA
COMPANIES VC JOBS NEWS CONTACT

union-therapeutics PRESS RELEASE ARCHIVE

Jun 21, 2023

UNION therapeutics announces positive topline results from the OSIRIS investigator-initiated proof-of-concept study of oral orismilast in patients with hidradenitis suppurativa USA - English USA - English

May 10, 2023

UNION therapeutics to present at 4th Annual Dermatology Drug Development Summit Europe USA - English USA - English

Apr 21, 2023

UNION therapeutics to participate at Kempen Life Science Conference

Jan 10, 2023

UNION therapeutics receives FDA Fast Track designation for oral orismilast for the treatment of moderate to severe hidradenitis suppurativa USA - English USA - English

Jan 10, 2023

UNION therapeutics receives FDA Fast Track designation for oral orismilast for the treatment of moderate to severe hidradenitis suppurativa USA - English USA - English

Jan 9, 2023

UNION therapeutics announces positive topline results from the IASOS Phase 2b study of oral orismilast in patients with moderate to severe psoriasis USA - English USA - English

Jan 9, 2023

UNION therapeutics announces positive topline results from the IASOS Phase 2b study of oral orismilast in patients with moderate to severe psoriasis USA - English USA - English

Dec 4, 2022

Innovent and UNION Therapeutics Announce First Subject Dosed in a Chinese Clinical Phase I Study of the Novel PDE4 Inhibitor Orismilast (IBI353)

Aug 4, 2022

UNION therapeutics announces enrollment of the first patient in ADESOS Phase 2b study of orismilast MR tablet in patients with atopic dermatitis

Jan 4, 2022

UNION therapeutics announces enrollment of first patient in the IASOS Phase 2b study of oral orismilast in psoriasis patients

Nov 4, 2021

UNION therapeutics receives FDA Fast Track designation for oral orismilast for the treatment of moderate to severe atopic dermatitis

Oct 14, 2021

UNION therapeutics announces enrollment of first patient in the OSIRIS Phase 2a study of oral orismilast for the treatment of mild to severe hidradenitis suppurativa

Sep 28, 2021

UNION therapeutics and Innovent Biologics enter into strategic collaboration and license agreement for orismilast, a next-generation PDE4 inhibitor for inflammatory dermatology conditions

Sep 27, 2021

Innovent and UNION Therapeutics Enter into Strategic Collaboration and License Agreement for Orismilast, a Next-generation PDE4 Inhibitor for Inflammatory Dermatology Conditions

Apr 6, 2021

UNION therapeutics' COVID-19 candidates found to be well tolerated in Phase 1 Lancet publication

Feb 22, 2021

UNI91103, developed by UNION therapeutics A/S, selected as first agent for prophylactic COVID-19 "PROTECT-V" study in high-risk patients

Jan 7, 2021

UNION therapeutics A/S receives FDA approval for IND of oral next generation PDE4-inhibitor (orismilast) for investigation in plaque psoriasis

Oct 28, 2020

UNION therapeutics appoints Dr. Kim Kjoeller as Chief Executive Officer and further strengthens leadership by appointing Dr. Günter Ditzinger as Chief Technology Officer

Aug 24, 2020

UNION therapeutics A/S completes dosing of healthy volunteers with UNI911 (inhaled niclosamide) for COVID-19

Aug 13, 2020

UNION therapeutics A/S enters option agreement to acquire worldwide exclusive license for COVID-19 technologies developed by TFF Pharmaceuticals, Inc.

Aug 13, 2020

TFF Pharmaceuticals Enters into Worldwide Licensing Agreement with UNION therapeutics for its Thin Film Freezing Technology in Combination with niclosamide

Jul 21, 2020

UNION therapeutics announces acquisition of PDE4i compound class from LEO Pharma with oral lead candidate (orismilast) in Phase 2

Google Analytics Alternative